The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer

Recruiting

• Conditions: Pancreas Adenocarcinoma; MicroRNA
• Interventions: Genetic: MicroRNA (mir-642b-3p)

• Registration Number: NCT06497777
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-06
• Study First Submitted: 2024-07-05
• Study First Submitted QC: 2024-07-05
• Last Update Submitted: 2024-07-05
• Study Start: 2024-07-06
• Study First Posted: 2024-07-12
• Last Update Posted: 2024-07-12
• Primary Completion: 2025-06-01
• Study Completion: 2026-06-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Pancreatic ductal adenocarcinoma
• Proven by pathology
• Patients who have not received anti-cancer therapies

Exclusion Criteria

• Less than 20 years old
• Unable to provide inform and consent
• Patients who have active malignancy other than pancreatic adenocarcinoma
• Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing
• Life expectancy less than 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Pancreatic adenocarcinoma	MicroRNA (mir-642b-3p)	Pancreatic adenocarcinoma which are proven by pathology, before initiation of anti-cancer treatment.

Primary Outcome Measures

Name	Time	Method
Ratio of the target microRNA in patients with and without pancreatic adenocarcinoma.	24 hours

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan